Important information about replacement of product supplier
STENOCARE has chosen to stop importing and distributing our three medical cannabis oil products “STENOCARE DROPS”. The reason is that the product supplier had a case with the Canadian authorities for using not yet approved grow rooms for cultivation. STENOCARE and the supplier have agreed to end the coorporation and supply of products.
STENOCARE has decided to follow a multi-supplier strategy to secure product availability for patients.
STENOCARE has entered into cooperation with new suppliers of medical cannabis oil products, whom we are working on getting approved for the Danish medical cannabis pilot programme. At this time, we cannot provide a date for these products to be ready for import and distribution in Denmark.
Supply agreement with Panaxia Pharmaceutical Industries Israel Ltd
STENOCARE has entered into a supply agreement with Panaxia Pharmaceutical Industries Israel Ltd.
This is an important next step in our multi-supplier strategy to offer patients more choice in their treatment with prescription-based medical cannabis and strengthen our supply chain.
We have at the same time submitted product approval applications for the Danish Medicines Agency.
Hear the news from Thomas Skovlund Schnegelsberg, CEO of STENOCARE A/S
Legalisation of medical cannabis in 2018
On 1st January 2018, medicinal cannabis by a doctor’s prescription and dispensed from a Danish pharmacy was legalised in Denmark with the “Pilot Programme”.
The Danish rules for medicinal cannabis are among the most demanding and restrictive in the world. The aim is to achieve the best patient safety with the products through documented production uniformity and quality under the control of the Danish Medicines Agency’s inspectors.
Legal medicinal cannabis products
On the website of the Danish Medicines Agency you can find an overview of legal medicinal cannabis products that are covered by the pilot programme, and which are therefore legally available for doctors’ prescriptions and dispensing by the pharmacies in Denmark. Products purchased on the Internet or purchased without a prescription abroad are not legal in Denmark, and are therefore not subject to inspection and approval by the Danish Medicines Agency.
STENOCARE has their headquarter and own cultivation facility in Denmark, and a wholly owned subsidiary in Ireland.
The company is built to operate in the highly regulated markets that are under the jurisdiction and control by the Danish Medicines Agency and their international sister agencies. The company has been a first-mover to bring prescription-based medical cannabis to marked. The strategy is to expand into more European countries with prescription-based medical cannabis products that meet the treatment needs of a diverse group of patients.
The Danish Medicines Agency controls companies that manufacture medicines – both before and after launching the medicine in the market. The Danish Medicines Agency also controls companies that sell medicines.
Only companies authorised by the Danish Medicines Agency are allowed to manufacture and sell medicines in Denmark.
STENOCARE is authorised by the Danish Medicines Agency to cultivate and handle cannabis for the purpose of developing cannabis for medicinal use, to manufacture cannabis intermediate products, and to engage in activities with euphoriant substances.